BREAST CANCER-RELATED ARM LYMPHEDEMA: INCIDENCE RATES, DIAGNOSTIC TECHNIQUES, OPTIMAL MANAGEMENT AND RISK REDUCTION STRATEGIES
Identifieur interne : 005467 ( Main/Exploration ); précédent : 005466; suivant : 005468BREAST CANCER-RELATED ARM LYMPHEDEMA: INCIDENCE RATES, DIAGNOSTIC TECHNIQUES, OPTIMAL MANAGEMENT AND RISK REDUCTION STRATEGIES
Auteurs : Chirag Shah [États-Unis] ; Frank A. Vicini [États-Unis]Source :
- International journal of radiation oncology, biology, physics [ 0360-3016 ] ; 2011.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Femme.
English descriptors
- KwdEn :
Abstract
As more women survive breast cancer, long-term toxicities affecting their quality of life, such as lymphedema (LE) of the arm, gain importance. Although numerous studies have attempted to determine incidence rates, identify optimal diagnostic tests, enumerate efficacious treatment strategies and outline risk reduction guidelines for breast cancer-related lymphedema (BCRL), few groups have consistently agreed on any of these issues. As a result, standardized recommendations are still lacking. This review will summarize the latest data addressing all of these concerns in order to provide patients and health care providers with optimal, contemporary recommendations. Published incidence rates for BCRL vary substantially with a range of 2-65% based on surgical technique, axillary sampling method, radiation therapy fields treated, and the use of chemotherapy. Newer clinical assessment tools can potentially identify BCRL in patients with subclinical disease with prospective data suggesting that early diagnosis and management with noninvasive therapy can lead to excellent outcomes. Multiple therapies exist with treatments defined by the severity of BCRL present. Currently, the standard of care for BCRL in patients with significant LE is complex decongestive physiotherapy (CDP). Contemporary data also suggest that a multidisciplinary approach to the management of BCRL should begin prior to definitive treatment for breast cancer employing patient-specific surgical, radiation therapy, and chemotherapy paradigms that limit risks. Further, prospective clinical assessments before and after treatment should be employed to diagnose subclinical disease. In those patients who require aggressive locoregional management, prophylactic therapies and the use of CDP can help reduce the long-term sequelae of BCRL.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000133
- to stream PascalFrancis, to step Curation: 000824
- to stream PascalFrancis, to step Checkpoint: 000192
- to stream Main, to step Merge: 005514
- to stream Main, to step Curation: 005467
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">BREAST CANCER-RELATED ARM LYMPHEDEMA: INCIDENCE RATES, DIAGNOSTIC TECHNIQUES, OPTIMAL MANAGEMENT AND RISK REDUCTION STRATEGIES</title><author><name sortKey="Shah, Chirag" sort="Shah, Chirag" uniqKey="Shah C" first="Chirag" last="Shah">Chirag Shah</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Radiation Oncology, William Beaumont Hospital</s1><s2>Royal Oak, MI</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Vicini, Frank A" sort="Vicini, Frank A" uniqKey="Vicini F" first="Frank A." last="Vicini">Frank A. Vicini</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Radiation Oncology, William Beaumont Hospital</s1><s2>Royal Oak, MI</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Michigan</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0007626</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 12-0007626 INIST</idno><idno type="RBID">Pascal:12-0007626</idno><idno type="wicri:Area/PascalFrancis/Corpus">000133</idno><idno type="wicri:Area/PascalFrancis/Curation">000824</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000192</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000192</idno><idno type="wicri:doubleKey">0360-3016:2011:Shah C:breast:cancer:related</idno><idno type="wicri:Area/Main/Merge">005514</idno><idno type="wicri:Area/Main/Curation">005467</idno><idno type="wicri:Area/Main/Exploration">005467</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">BREAST CANCER-RELATED ARM LYMPHEDEMA: INCIDENCE RATES, DIAGNOSTIC TECHNIQUES, OPTIMAL MANAGEMENT AND RISK REDUCTION STRATEGIES</title><author><name sortKey="Shah, Chirag" sort="Shah, Chirag" uniqKey="Shah C" first="Chirag" last="Shah">Chirag Shah</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Radiation Oncology, William Beaumont Hospital</s1><s2>Royal Oak, MI</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Vicini, Frank A" sort="Vicini, Frank A" uniqKey="Vicini F" first="Frank A." last="Vicini">Frank A. Vicini</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Radiation Oncology, William Beaumont Hospital</s1><s2>Royal Oak, MI</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Michigan</region></placeName></affiliation></author></analytic><series><title level="j" type="main">International journal of radiation oncology, biology, physics</title><title level="j" type="abbreviated">Int. j. radiat. oncol. biol. phys.</title><idno type="ISSN">0360-3016</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">International journal of radiation oncology, biology, physics</title><title level="j" type="abbreviated">Int. j. radiat. oncol. biol. phys.</title><idno type="ISSN">0360-3016</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Arm</term><term>Breast cancer</term><term>Cancerology</term><term>Clinical management</term><term>Complication</term><term>Diagnosis</term><term>Female</term><term>Incidence</term><term>Lymphedema</term><term>Risk factor</term><term>Technique</term><term>Woman</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cancer du sein</term><term>Lymphoedème</term><term>Bras</term><term>Incidence</term><term>Diagnostic</term><term>Technique</term><term>Conduite à tenir</term><term>Facteur risque</term><term>Cancérologie</term><term>Femelle</term><term>Femme</term><term>Complication</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Femme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">As more women survive breast cancer, long-term toxicities affecting their quality of life, such as lymphedema (LE) of the arm, gain importance. Although numerous studies have attempted to determine incidence rates, identify optimal diagnostic tests, enumerate efficacious treatment strategies and outline risk reduction guidelines for breast cancer-related lymphedema (BCRL), few groups have consistently agreed on any of these issues. As a result, standardized recommendations are still lacking. This review will summarize the latest data addressing all of these concerns in order to provide patients and health care providers with optimal, contemporary recommendations. Published incidence rates for BCRL vary substantially with a range of 2-65% based on surgical technique, axillary sampling method, radiation therapy fields treated, and the use of chemotherapy. Newer clinical assessment tools can potentially identify BCRL in patients with subclinical disease with prospective data suggesting that early diagnosis and management with noninvasive therapy can lead to excellent outcomes. Multiple therapies exist with treatments defined by the severity of BCRL present. Currently, the standard of care for BCRL in patients with significant LE is complex decongestive physiotherapy (CDP). Contemporary data also suggest that a multidisciplinary approach to the management of BCRL should begin prior to definitive treatment for breast cancer employing patient-specific surgical, radiation therapy, and chemotherapy paradigms that limit risks. Further, prospective clinical assessments before and after treatment should be employed to diagnose subclinical disease. In those patients who require aggressive locoregional management, prophylactic therapies and the use of CDP can help reduce the long-term sequelae of BCRL.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Michigan</li></region></list><tree><country name="États-Unis"><region name="Michigan"><name sortKey="Shah, Chirag" sort="Shah, Chirag" uniqKey="Shah C" first="Chirag" last="Shah">Chirag Shah</name></region><name sortKey="Vicini, Frank A" sort="Vicini, Frank A" uniqKey="Vicini F" first="Frank A." last="Vicini">Frank A. Vicini</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005467 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005467 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:12-0007626
|texte= BREAST CANCER-RELATED ARM LYMPHEDEMA: INCIDENCE RATES, DIAGNOSTIC TECHNIQUES, OPTIMAL MANAGEMENT AND RISK REDUCTION STRATEGIES
}}
| This area was generated with Dilib version V0.6.31. |  |